好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Health Economic Impact of Skin Biopsy Detection of Phosphorylated Alpha-synuclein in a Private Practice
Movement Disorders
P9 - Poster Session 9 (5:00 PM-6:00 PM)
17-010
To evaluate the health economic impact of skin biopsy detection of phosphorylated alpha-synuclein (P-SYN) in patients with suspected synucleinopathies.
Skin biopsy detection of P-SYN is a new biomarker supporting the diagnosis of patients with suspected synucleinopathies. However, the economic impact of skin biopsy detection of P-SYN in clinical care has not been explored.  

A retrospective chart review was completed on 100 patients with suspected synucleinopathy that completed P-SYN testing in a private practice between January 2022 and December 2024.  Extracted data included the number of neurologic diagnostic procedures, tests, treatments, and referrals before and after P-SYN testing. Average costs in Louisville, KY, were used to determine the total financial burden (mdsave.com). The final estimated costs were normalized on an annual basis (at 2025 pricing) to account for differences in duration of treatment and follow-up.
50 males and 50 females (73±8 years) were included in this study. Length of evaluation before P-SYN testing was 26.1±10.3 months, and length of follow-up after P-SYN testing was 14.6±6.8 months. A total of 599 tests were ordered for the cohort, with 69% (413/599) ordered before the Syn-One test. Significant reductions in all tests were noted after Syn-One testing (P<0.01, all groups).  Before P-SYN testing, 89 MRIs and 20 DaTscans were completed; In comparison, after P-SYN testing 23 MRIs and 6 DaTscans were completed. Neurological health care costs for the cohort was $587,000. The cohort spent $172,000 more before the cutaneous P-SYN testing. Healthcare expenditure after cutaneous P-SYN testing decreased by $100,521 annually.   At a practice level, 135 DaTScan’s were ordered annually prior to introduction of P-SYN testing, and 33 DaTScan’s were ordered annually after introduction of P-SYN testing.   
The economic burden for suspected synucleinopathies for neurological care is significantly reduced after cutaneous P-SYN testing.  Reductions in neuroimaging, laboratory studies, and physician referrals drove cost savings.  
Authors/Disclosures
Christopher H. Gibbons, MD, FAAN (Beth Israel Deaconess Medical Center)
PRESENTER 		Dr. Gibbons has received personal compensation for serving as an employee of CND Life Sciences. Dr. Gibbons has or had stock in CND Life Sciences.Dr. Gibbons has received publishing royalties from a publication relating to health care.
Colin Gibbons An immediate family member of Mr. Gibbons has stock in CND Life Sciences.
Roy L. Freeman, MD (Beth Israel Deaconess Hosp) Dr. Freeman has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Cutaneous Diagnostic Life Sciences. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vertex. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Theravance. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Inhibikase. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. The institution of Dr. Freeman has received research support from NIH. The institution of Dr. Freeman has received research support from Theravance. The institution of Dr. Freeman has received research support from Biohaven. The institution of Dr. Freeman has received research support from Lundbeck. Dr. Freeman has received research support from Regeneron.
Nicole P. Murray, NP (Honor Health Neurology) Miss Murray has nothing to disclose.
Alexandria Swanson, PA Mrs. Swanson has received personal compensation for serving as an employee of CND Life Sciences.
Jason L. Crowell, MD, FAAN (Norton Neuroscience Institute) Dr. Crowell has nothing to disclose.
Justin T. Phillips, MD (Norton Neuroscience Institute) Dr. Phillips has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Phillips has a non-compensated relationship as a Treasurer with Commonwealth Neurologic Society that is relevant to AAN interests or activities.
Sarrah Marcotte Miss Marcotte has received personal compensation for serving as an employee of CND Life Sciences.
Jourdan Parent, PhD Dr. Parent has received personal compensation for serving as an employee of CND Life Sciences.
Manuel X. Duval, PhD Mr. Duval has received personal compensation for serving as an employee of CND Life sciences.
Todd D. Levine, MD (Honor Health) Dr. Levine has received personal compensation for serving as an employee of CND life sciences . Dr. Levine has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Nufactor. Dr. Levine has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for PNA. Dr. Levine has or had stock in CND Life Sciences.Dr. Levine has or had stock in Corinthian reference lab.